Ingevity Corporation

NYSE:NGVT 주식 리포트

시가총액: US$2.7b

Ingevity 과거 순이익 실적

과거 기준 점검 0/6

Ingevity 의 수입은 연평균 -59.3%의 비율로 감소해 온 반면, Chemicals 산업은 연평균 0.6%의 비율로 증가했습니다. 매출은 연평균 0.8%의 비율로 감소해 왔습니다.

핵심 정보

-59.33%

순이익 성장률

-59.04%

주당순이익(EPS) 성장률

Chemicals 산업 성장률12.93%
매출 성장률-0.80%
자기자본이익률-506.06%
순이익률-12.87%
다음 순이익 업데이트07 May 2026

최근 과거 실적 업데이트

Recent updates

NGVT: Future P/E Will Reflect Margin Resilience And Impairment Charge Impact

Analysts have increased their price target for Ingevity to $80.50 from $79.25, citing updated assumptions on long term revenue growth, profit margin resilience, and future P/E levels reflected in recent research, including the Wells Fargo target increase. Analyst Commentary Recent research behind the new US$80.50 price target focuses on refreshed assumptions for long term revenue trends, margin resilience, and the P/E level that investors may be willing to ascribe to Ingevity over time.

NGVT: Future P/E Will Depend On Margin Execution And Impairment Fallout

Analysts have raised their price target on Ingevity by $5 to $79.25, citing updated assumptions regarding discount rates, long-term revenue growth, profit margins, and future P/E expectations. Analyst Commentary Analysts raising the price target to $79.25 are updating their models to reflect changes in discount rates, long term revenue assumptions, profit margins, and future P/E expectations.

NGVT: Higher P/E Will Rely On Future Margin Delivery

Analysts have lifted their price target on Ingevity by $5 to $79.25, citing updated assumptions on discount rates, long term revenue growth, profit margins, and future P/E, which support a slightly higher valuation outlook. Analyst Commentary Bullish Takeaways Bullish analysts see the higher price target as consistent with updated assumptions on discount rates and long term revenue growth, which they believe better reflect the company’s current risk profile and earnings potential.

NGVT: Higher P/E Outlook Will Depend On Margin Execution

Analysts have raised their price target on Ingevity by $8.50 to $79.25, citing updated views on revenue growth, profit margins, and an expected higher future P/E multiple. Analyst Commentary Recent Street research has focused on how Ingevity might justify a higher valuation, with specific attention on revenue trends, profitability, and the potential for the shares to support a richer P/E multiple over time.

NGVT: Updated P/E Assumptions And Buybacks Will Shape Balanced Outlook

Analysts have raised their price target on Ingevity by $5 to $70.75, citing updated assumptions around discount rates and future P/E as the main factors behind this revised view. Analyst Commentary Analysts framing the new US$70.75 price target are focusing less on short term headlines and more on what updated discount rate and P/E assumptions imply for Ingevity's risk profile and execution needs.

NGVT: Share Repurchases And Battery Materials License Will Guide Balanced Outlook

Analysts have raised their price target on Ingevity from US$69.50 to US$70.75, citing updated assumptions around discount rates, revenue trends, profit margins and future P/E expectations. Analyst Commentary Analysts who support the higher price target describe it as a fine tuning of their models rather than a wholesale rethink.

NGVT: Buybacks And Battery Materials License Will Shape Balanced Outlook

Analysts have maintained their fair value estimate for Ingevity at US$69.50, with only minor adjustments to inputs such as the discount rate and long-term P/E assumptions. These changes reflect updated modeling rather than a change in conviction.

NGVT: Battery Additives And Buybacks Will Shape Balanced Long-Term Outlook

Analysts have adjusted their price target on Ingevity to US$69.50. This reflects updated views on the discount rate, revenue outlook, profit margins and future P/E assumptions.

NGVT: Future Battery Materials Role Will Drive Long-Term Upside Despite Margin Reset

Analysts have modestly raised their price target on Ingevity by about $1.25 to approximately $69.50. They cite a lower perceived discount rate and an improving revenue trajectory, which more than offset concerns about a structurally lower profit margin and a higher future valuation multiple.

NGVT: Future Battery Materials Role Will Drive Stronger Long Term Upside Potential

Analysts have nudged their price target on Ingevity higher from $65.25 to $68.25, citing a modestly richer future earnings multiple that more than offsets slightly softer revenue growth and margin assumptions. What's in the News Ingevity announced that Executive Vice President and Chief Financial Officer Mary Dean Hall will transition from her role effective May 1, 2026, and remain in an advisory capacity for one year, as part of a planned leadership change.

Is There Now An Opportunity In Ingevity Corporation (NYSE:NGVT)?

Sep 30
Is There Now An Opportunity In Ingevity Corporation (NYSE:NGVT)?

Does Ingevity (NYSE:NGVT) Have A Healthy Balance Sheet?

Sep 06
Does Ingevity (NYSE:NGVT) Have A Healthy Balance Sheet?

Ingevity: No Specialty Play, Awaiting External Drivers

Sep 05

Portfolio Repositioning And Engineered Additives Will Create A Sustainable Future

Consensus analyst price targets for Ingevity have risen to $65.25, reflecting increased confidence in continued earnings and free cash flow growth following a strong Q2 beat and improved operational outlook. Analyst Commentary Q2 earnings beat, demonstrating stronger-than-expected financial performance.

Portfolio Repositioning And Engineered Additives Will Create A Sustainable Future

The upward revision in Ingevity's revenue growth forecasts from 2.6% to 3.7% per annum has outweighed the impact of a higher discount rate, resulting in an increased consensus analyst price target from $54.25 to $57.00. What's in the News Ingevity Corporation maintained its earnings guidance for 2025, expecting sales between $1.25 billion and $1.40 billion.

Ingevity Corporation (NYSE:NGVT) Shares Could Be 39% Below Their Intrinsic Value Estimate

Jun 27
Ingevity Corporation (NYSE:NGVT) Shares Could Be 39% Below Their Intrinsic Value Estimate

Subdued Growth No Barrier To Ingevity Corporation (NYSE:NGVT) With Shares Advancing 33%

May 28
Subdued Growth No Barrier To Ingevity Corporation (NYSE:NGVT) With Shares Advancing 33%
User avatar

Premium Markets Will Secure Long Term Value

Expansion into premium specialty chemicals and advanced materials is increasing margins and positioning for growth as sustainability trends and vehicle electrification accelerate.

Why We're Not Concerned Yet About Ingevity Corporation's (NYSE:NGVT) 32% Share Price Plunge

Apr 05
Why We're Not Concerned Yet About Ingevity Corporation's (NYSE:NGVT) 32% Share Price Plunge

Ingevity (NYSE:NGVT) Has A Somewhat Strained Balance Sheet

Feb 20
Ingevity (NYSE:NGVT) Has A Somewhat Strained Balance Sheet

Ingevity Corporation (NYSE:NGVT) Shares Could Be 49% Below Their Intrinsic Value Estimate

Jan 16
Ingevity Corporation (NYSE:NGVT) Shares Could Be 49% Below Their Intrinsic Value Estimate

What Ingevity Corporation's (NYSE:NGVT) 32% Share Price Gain Is Not Telling You

Nov 07
What Ingevity Corporation's (NYSE:NGVT) 32% Share Price Gain Is Not Telling You

Is Ingevity (NYSE:NGVT) A Risky Investment?

Oct 13
Is Ingevity (NYSE:NGVT) A Risky Investment?

Ingevity Corporation's (NYSE:NGVT) Prospects Need A Boost To Lift Shares

Sep 08
Ingevity Corporation's (NYSE:NGVT) Prospects Need A Boost To Lift Shares

Ingevity: The Risk-Reward Ratio Is Still Unfavorable

Aug 27

Ingevity Corporation Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Aug 03
Ingevity Corporation Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Ingevity (NYSE:NGVT) Use Of Debt Could Be Considered Risky

Jul 13
Ingevity (NYSE:NGVT) Use Of Debt Could Be Considered Risky

Should You Investigate Ingevity Corporation (NYSE:NGVT) At US$45.90?

Jun 14
Should You Investigate Ingevity Corporation (NYSE:NGVT) At US$45.90?

Are Investors Undervaluing Ingevity Corporation (NYSE:NGVT) By 44%?

Apr 18
Are Investors Undervaluing Ingevity Corporation (NYSE:NGVT) By 44%?

Is Ingevity (NYSE:NGVT) A Risky Investment?

Mar 22
Is Ingevity (NYSE:NGVT) A Risky Investment?

What Is Ingevity Corporation's (NYSE:NGVT) Share Price Doing?

Jan 23
What Is Ingevity Corporation's (NYSE:NGVT) Share Price Doing?

Ingevity Corporation (NYSE:NGVT) Doing What It Can To Lift Shares

Jan 04
Ingevity Corporation (NYSE:NGVT) Doing What It Can To Lift Shares

These Analysts Just Made An Incredible Downgrade To Their Ingevity Corporation (NYSE:NGVT) EPS Forecasts

Nov 10
These Analysts Just Made An Incredible Downgrade To Their Ingevity Corporation (NYSE:NGVT) EPS Forecasts

매출 및 비용 세부 내역

Ingevity가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.

순이익 및 매출 추이

NYSE:NGVT 매출, 비용 및 순이익 (USD Millions)
날짜매출순이익일반관리비연구개발비
31 Dec 251,168-15017128
30 Sep 251,382-36117731
30 Jun 251,383-35417130
31 Mar 251,350-35416329
31 Dec 241,200-12115825
30 Sep 241,309-25816325
30 Jun 241,421-28016527
31 Mar 241,640-11218330
31 Dec 231,21610616225
30 Sep 231,70412719632
30 Jun 231,74017721032
31 Mar 231,67820220732
31 Dec 221,66821219830
30 Sep 221,62122519130
30 Jun 221,51614618129
31 Mar 221,45413017927
31 Dec 211,39211817926
30 Sep 211,38113516925
30 Jun 211,33620916024
31 Mar 211,24818515123
31 Dec 201,21618115023
30 Sep 201,19418015322
30 Jun 201,22217015921
31 Mar 201,30420616321
31 Dec 191,29318416320
30 Sep 191,26818215820
30 Jun 191,21917115221
31 Mar 191,17516114522
31 Dec 181,13416913322
30 Sep 181,08516912522
30 Jun 181,03715311621
31 Mar 1898913810720
31 Dec 1797212710720
30 Sep 179549410419
30 Jun 179425310318
31 Mar 179274510018
31 Dec 16908359618
30 Sep 16898349313
30 Jun 1690264959
31 Mar 16919661055
31 Dec 15958809317
30 Sep 15999991078
30 Jun 151,0251151088

양질의 수익: NGVT 은(는) 현재 수익성이 없습니다.

이익 마진 증가: NGVT는 현재 수익성이 없습니다.

잉여현금흐름 대비 순이익 분석

과거 순이익 성장 분석

수익추이: NGVT은 수익성이 없으며 지난 5년 동안 손실이 연평균 59.3% 증가했습니다.

성장 가속화: 현재 수익성이 없어 지난 1년간 NGVT의 수익 성장률을 5년 평균과 비교할 수 없습니다.

수익 대 산업: NGVT은 수익성이 없어 지난 해 수익 성장률을 Chemicals 업계(0.1%)와 비교하기 어렵습니다.

자기자본이익률

높은 ROE: NGVT는 현재 수익성이 없으므로 자본 수익률이 음수(-506.06%)입니다.

총자산이익률

투하자본수익률

우수한 과거 실적 기업을 찾아보세요

7D

1Y

7D

1Y

7D

1Y

기업 분석 및 재무 데이터 상태

데이터최종 업데이트 (UTC 시간)
기업 분석2026/05/06 02:53
종가2026/05/06 00:00
수익2025/12/31
연간 수익2025/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지데이터기간미국 소스 예시 *
기업 재무제표10년
  • 손익계산서
  • 현금흐름표
  • 대차대조표
분석가 컨센서스 추정치+3년
  • 재무 예측
  • 분석가 목표주가
시장 가격30년
  • 주가
  • 배당, 분할 및 기타 조치
지분 구조10년
  • 주요 주주
  • 내부자 거래
경영진10년
  • 리더십 팀
  • 이사회
주요 개발10년
  • 회사 공시

* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Ingevity Corporation는 8명의 분석가가 다루고 있습니다. 이 중 4명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가기관
Paretosh MisraBerenberg
John McNultyBMO Capital Markets Equity Research
Jonathan TanwantengCJS Securities, Inc.